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Abstract 
Background: The role of single nucleotide polymorphisms (SNPs) associated with inflammatory bowel disease (IBD) 
is gaining interest. With the advent of novel therapies, personalized treatment in IBD is a future goal. We wondered 
whether IBD-associated SNPs are able to predict response to anti-TNFα treatment.
Methods: Data on treatment use and primary response, loss of response and side effects to anti-TNFα treatments 
were retrieved for 570 IBD patients. rs13361189 (IRGM), rs10210302 (ATG16L1), rs2066844, rs2066845, rs2066847 
(NOD2), rs35873774 (XBP1), rs11175593 (LRRK2), rs11465804 (IL23R), rs2301436 (CCR6), rs744166 (STAT3) and rs4821544 
(NCF4) SNP status were determined.
Results: No associations were found between genetic variants of the LRRK2, CCR6, IL23R and NCF4 genes and 
response to anti-TNFα. For NOD2 and XBP1 associations were found, however, these associations were not strong 
enough to survive multiple testing corrections. Strikingly, patients carrying the ATG16L1 T300A variant were more 
likely to be treated with adalimumab, even after correction for disease phenotype, disease behavior and age 
(p = 0.004, OR 2.8, CI 1.6–5.0).
Conclusions: Genetic polymorphisms in the known IBD-associated gene ATG16L1 correlate with requirement of 
treatment, suggesting a different IBD disease phenotype in these patients. Further investigation will need to elucidate 
the implications of these findings and identify the underlying disease characteristics.
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Background
Inflammatory Bowel diseases, comprising of Crohn’s dis-
ease (CD), Ulcerative colitis (UC) and IBD-unclassified 
(IBD-U), are multifactorial in their etiology.
In the last two decades, the introduction of the anti-
tumor necrosis factor-α (anti-TNFα) drugs (e.g. inf-
liximab and adalimumab) has expanded the treatment 
arsenal with drugs potent for both inducing remission 
as well as maintaining remission [1–3]. Although these 
immunosuppressants are increasingly used, the need 
for intestinal surgery remains unchanged, with 25–61% 
of newly diagnosed IBD requiring surgery at least once 
within the first 5  years after diagnosis [4–6]. Addition-
ally, anti-TNFα treatments are not effective in 20–40% 
of IBD patients and loss of response and/or is seen in a 
substantial proportion of the patients [1, 7–10]. While it 
has been suggested that earlier treatment with anti-TNFα 
could improve disease outcome [11], we were previously 
unable to confirm a benefit for earlier anti-TNFα treat-
ment on IBD-disease complications [12]. The most likely 
explanation appeared to be that an inappropriate selec-
tion of patients eligible for therapy had led to suboptimal 
treatment and subsequently outcome.
Genetics play an important role in IBD, as IBD shows 
a large hereditary component and genetic variants may 
influence cellular functions, the innate immune sys-
tem and thereby both disease activity and response to 
treatment [13, 14]. Genome-wide association studies 
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(GWAS) have identified over 163 single-nucleotide pol-
ymorphisms (SNPs) that are associated with IBD [15, 
16]. Based on their known function in normal cellular 
settings, efforts have been made to cluster these SNPs 
into functional categories in order to glean insight into 
the mechanistic aspects of IBD pathology [17, 18]. Key 
pathways identified so far are innate immunity, defective 
epithelial barrier, autophagy, IL10 signaling and adap-
tive immunity, although these definitions are not always 
clear-cut, with many genes acting in more than one of 
these categories. While the general role of these genes 
in cellular processes is in most cases known, it is as yet 
largely unclear how the IBD-associated SNPs in these 
genes affect cellular function, or how such changed cel-
lular functions would contribute to the development 
of IBD. However, there are some positive exceptions. 
For instance, the IBD-associated variants in the NOD2, 
ATG16L1 and IRGM genes affect cellular autophagy 
processes and bacterial clearance in (innate) immune 
cells, and may affect bacterial composition of the gut in 
patients with IBD [19–22]. In addition, SNPs in the inter-
leukin 23 receptor gene (IL23R) were recently shown to 
affect expression of the anti-microbial peptide DMBT1 
in intestinal epithelial cells in IBD [23]. Our own studies 
demonstrated that an IBD-associated SNP in the neutro-
phil cytosolic factor 4 (NCF4) gene results in a decreased 
antimicrobial function of granulocytes, as demonstrated 
by a reduced production of reactive oxygen species by 
these cells [24]. In light of the immune-cell modulatory 
properties of several of the known IBD-associated SNPs, 
it is likely that these SNPs may affect response of patients 
to immune-modulatory drugs as well.
Identifying associations between patients’ genetics and 
characteristics and response to treatment would open up 
the possibility of implementing personalised treatment 
strategies. Tailored strategies in the future could include 
treatment according to the individual patients’ genetic 
profile. With this study we aimed to identify patients 
likely to benefit from anti-TNFα treatment, based on 
their genetic profile.
Methods
All patients of whom DNA was available at the Eras-
mus MC University Medical Center, and the diagnosis 
of IBD could be confirmed according to the Lennard-
Jones criteria, were included in this study [25]. Disease 
characteristics were scored according to the Montreal 
criteria [26]. Patients having had a liver transplantation 
or suffering from auto-immune hepatitis or PSC and 
who were treated for these conditions, were excluded 
from analysis. Data on patient and disease characteristics 
were obtained from the patients’ medical charts. For each 
patient, the following characteristics were retrieved: date 
of birth, date of IBD diagnosis, age at diagnosis, date of 
first visit to the Erasmus MC University Medical Centre, 
IBD phenotype, gender, comorbidities, familial IBD sta-
tus, disease location, disease behavior, extra-intestinal 
manifestations, fistula and abscesses and the amount of 
surgery. SNP carriers were compared to non-SNP car-
riers for above mentioned parameters. For disease loca-
tion and behavior, patients with IBDU were classified 
as patients with UC. Maximum disease extension and 
disease characterization were scored according to the 
Montreal criteria [26]. Number of flares during follow-
up were scored based on clinical and endoscopic param-
eters. End of follow-up was January 1st, 2013. This study 
was approved by the institutional medical ethical board 
of the Erasmus MC (MEC-2012-245).
Of all patients, records pertaining to infliximab (IFX) 
and adalimumab (ADA) use were perused. Of the treat-
ments, their use, side-effects and primary non-response 
and loss of response were evaluated. Primary nonre-
sponse to biologic therapy was defined as an absence of 
symptomatic improvement with persistently high levels 
of C-reactive protein (CRP) after induction treatment. 
Long-term sustained response to biologics was defined 
as improvement of the symptoms lasting at least 1  year 
without any further adjustments of the therapeutic regi-
men. Failure of the therapeutic regimen was defined by 
an absence of improvement of the symptoms of disease 
and by a decision of the treating physician to add ster-
oids, add another immunosuppressor, switch to another 
immunosuppressor, switch to another anti-TNF medica-
tion (adalimumab), or refer for CD-related surgery.
Several immune-regulatory genes were selected for 
this study. We focused on genes involved in innate 
immunity/autophagy/bacterial clearance in both in 
blood immune cells and Paneth cells (IRGM, NOD2, 
LRRK2, ATG16L1, XBP1 and NCF4) [19, 24, 27, 
28] and genes affecting adaptive immune responses 
(IL23R, STAT3, CCR6) [29, 30]. Rs13361189 (IRGM), 
rs10210302 (ATG16L1), rs2066844, rs2066845, 
rs2066847 (NOD2), rs35873774 (XBBP1), rs11175593 
(LRRK2), rs11465804 (IL23R), rs2301436 (CCR6), 
rs744166 (STAT3) and rs4821544 (NCF4) SNP status 
were determined by KBiosciences, UK. Inconclusive 
SNP analyses were excluded, accounting for the variable 
number of patients analyzed per SNP (Additional file 1: 
Table S1). Different SNPs in NOD2 were combined for 
analysis, as these SNPS have been shown to alter cellu-
lar function in a similar manner [31, 32]. Due to the low 
number of patients homozygous for the SNPs, patients 
heterozygous for the risk allele were analysed together 
with patients carrying two risk alleles of the same gene, 
thereby comparing carriers and non-carriers of the 
IBD-associated alleles.
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Statistical analyses were performed using descrip-
tive statistics, independent t tests, Mann–Whitney non-
parametric tests, Chi square (Χ2) tests and Fisher’s exact 
test. Independent samples t tests were used to compare 
means. Proportions were compared using the Χ2 test or 
Fisher’s exact test. Two-sided p values < 0.05 were con-
sidered significant. Associations were assessed using 
a logistic regression using the enter method expressed 
as odds ratios (OR) with 95% confidence interval (CI). 
Correction for multiple testing was applied to logistic 
regression analysis, with two-sided p values of  <  0.0055 
considered significant correction for multiple testing. 
Overall logistic analysis associating IFX to the SNPs in 
the IBD related genes were corrected for age, IBD sub-
type and fistulising disease. Subanalyses in CD patients 
were corrected for fistula and age. Subanalyses for UC 
were corrected for age. Logistic analyses aiming to asso-
ciate ADA to the SNPs were corrected for extra-intestinal 
manifestations, age, and IBD subtype. Subanalyses in CD 
patients were corrected for extra-intestinal manifesta-
tions, fistula and age. Subanalyses in UC patients were 
corrected for extra-intestinal manifestations and age. Sta-
tistical analyses were performed using SPSS for Windows 
software (v23.0, Chicago, IL).
Results
Patient and disease characteristics
Of the 591 eligible patients, 19 were excluded due to liver 
disease or liver transplantation, one patient was not suf-
fering from IBD, and one patient was excluded because 
of multiple kidney transplantations, leaving a total of 570 
patients. Thede included 411 CD (71.9%), 148 UC (26.0%) 
and 11 IBDU (1.9%) patients. Patient and disease char-
acteristics are shown in Table 1. The median age at IBD 
diagnosis was 27 years (range 5–79). Median age at diag-
nosis was 25 years in CD, 26 years in UC, and 32 years 
in IBDU. Of our patients 54.7% were female. The mean 
duration of follow-up was 9.2 years (range 0.1–49.1). Four 
patients developed colorectal cancer during follow-up.
In total 211 patients were treated with IFX and 179 
with ADA, with 111 patients receiving both treatments. 
A total of 126 patients developed side effects while 
treated with IFX and 89 did so while on ADA. Fifty-nine 
patients experienced loss of response to IFX and 26 to 
ADA. Twenty-seven patients were primary non-respond-
ers on IFX and 14 never responded to ADA.
CD patients were more likely to be treated with IFX 
(p  =  0.022, OR 1.6, CI 1.1–2.3) or ADA (p  <  0.0001, 
OR 7.6, CI 4.2–13.9) compared to UC/IBDU patients. 
IFX treated patients were less likely to achieve mucosal 
healing than patients not requiring this medication 
(p < 0.0001, OR 0.48). Both IFX (p < 0.0001, OR 2.5) and 
ADA (p  =  0.002, OR 1.8) treated patients were more 
likely to undergo bowel resection, compared to patients 
not receiving these medications. However these associa-
tions were no longer significant after correction for fis-
tula and disease phenotype. Furthermore ADA treated 
patients suffered from extra-intestinal manifestations 
(p < 0.012) more often than patients who were not treated 
with ADA, which remained significant after correction 
for disease phenotype (p = 0.047, OR 1.5, CI 1.0–2.2).
Genetics
SNPs in nine IBD related genes were evaluated. Distribu-
tion of the genetic profiles can be found in Table 2. The 
minor allele frequency known in literature and the fre-
quency in this cohort can be found in Table 3. 
An association between the ATG16L1 risk allele and 
Crohn’s disease (p  =  0.007) and younger age at IBD 
diagnosis (26.83 vs 29.93, p = 0.032) was observed. Sub 
analysis per disease phenotype showed that UC or IBDU 
patients carrying the ATG16L1 risk allele were less likely 
to achieve mucosal healing (p = 0.027). In CD patients, 
ATG16L1 SNP carriers were significantly more likely to 
have a family member with IBD (p = 0.004).
Carrying the IRGM risk allele was associated with male 
gender (p =  0.034) and younger age at diagnosis (25.84 
vs 27.90, p  =  0.048). Sub analysis for IBD phenotype 
did not how any differences between SNP carriers and 
non-carriers.
NOD2 risk allele carriers more often suffered from CD 
(p = 0.002) and carrying the NOD2 SNP was associated 
with colonic disease in these patients (p < 0.0001).
Carrying the CCR6 SNP was associated with achieve-
ment of mucosal healing in UC patients (p = 0.009).
CD patients carrying the NCF4 SNP were more likely 
to suffer from stenosing disease (p =  0.005, OR 2.0, CI 
1.2–3.2), even after correction for age (p = 0.004, OR 2.0, 
CI 1.2–3.3), although no association with fistula or non-
stenosis-non-fistulising disease was observed.
IL23R CD SNP patients were also more likely to suffer 
from stenosing disease (p = 0.023).
There were no differences in basic clinical parameters 
between patients carrying risk alleles of the XBP1, STAT3 
and LRRK2/MUC2 genes and patients who did not carry 
these risk alleles.
None of the risk alleles were associated with the num-
ber of flared (corrected for follow-up time).
Genetics versus treatments
The only significant association between anti-TNFα use 
and genetic risk variants was found for ATG16L1. While 
there were no associations between ATG16L1 risk allele 
carriers and IFX use/response, neither in the entire 
cohort, nor in CD and UC sub analyses, IBD patients car-
rying the ATG16L1 SNP were significantly more prone 
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to use ADA (p  =  0.004, OR 2.4, CI 1.3–4.4, corrected 
for age, extra-intestinal manifestations, IBD subtype and 
multiple testing). In CD patients, this correlation also 
remained true (p = 0.005 OR 2.6 CI 1.3–5.0).
Other, nominally significant associations are listed 
below.
Logistic regression analysis after correction for age 
and IBD phenotype showed that patients carrying the 
Table 1 Patient characteristics
All numbers are presented as n (%), unless stated otherwise
CD Crohn’s disease, UC ulcerative colitis, IBDU unclassified inflammatory bowel disease, CRC colorectal cancer, IBD inflammatory bowel disease, yrs years
Total
N = 570
CD
N = 411
UC
N = 148
IBDU
N = 11
Follow-up
 Length, mean, range 9.2 yrs (range 0.1–49.1) 9.5 yrs (range 0.1–49.1) 8.6 yrs (range 0.2–32.3) 4.9 yrs (range 0.8–10.5)
 Length, median 6.9 yrs 7.0 yrs 6.9 yrs 4.8 yrs
Gender
 Male 258 (45.3) 169 (41.1) 85 (57.4) 4 (36.4)
 Female 312 (54.7) 242 (58.9) 63 (42.6) 7 (63.6)
Age at diagnosis
 Mean, range 27 yr (range 5–79) 27 yr (range 5–79) 28 yr (range 8–69) 32 yr (range 17–47)
 Median 25 yr 25 yr 26 yr 32 yr
Disease location CD
 L1—terminal ileum 99 (24.1)
 L2—colon 90 (21.9)
 L3—ileocolon 120 (29.2)
 (+) L4—upper GI tract 63 (15.3)
 Other 0 (0)
 Unknown 21 (5.1)
 No inflammation 18 (4.4)
Disease location UC
 E1—proctitis 8 (5.0) 7 (4.7) 1 (9.1)
 E2—left sided colitis 69 (43.4) 64 (43.2) 5 (45.4)
 E3—pancolitis 73 (45.9) 69 (46.6) 4 (36.4)
 No inflammation 3 (1.9) 3 (2.0) 0 (0)
 Other 2 (1.3) 1 (0.7) 1 (9.1)
 Unknown 4 (2.5) 4 (2.7) 0
 Backwash ileitis 35 22 3
 Rectal sparing 19 16 1
Disease behaviour CD
 B1—luminal disease 126 (30.7)
 B2—stenosis 89 (21.7)
 B3—abscesses and/or fistula 181 (44.0)
 P—perianal disease 144 (35.0)
 Unknown 15 (3.6)
 Extra-intestinal 172 (30.2) 134 (32.6) 36 (24.3) 2 (18.2)
Family history of IBD
 Yes 127 (22.3) 98 (23.8) 25 (16.9) 4 (36.4)
 No 380 (66.7) 267 (65.0) 108 (73.0) 5 (45.4)
 Not documented 63 (11.0) 46 (11.2) 15 (10.1) 2 (18.2)
Family history of CRC
 Yes 36 (6.3) 22 (5.4) 13 (8.8) 1 (9.1)
 No 469 (82.3) 342 (83.2) 119 (80.4) 8 (72.7)
 Not documented 65 (11.4) 47 (11.4) 16 (10.8) 2 (18.2)
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IRGM risk allele were more prone to develop primary 
non response to IFX (OR 2.4, CI 1.0–5.7, p  =  0.048). 
In sub analysis per disease phenotype, it was apparent 
that in particular UC patients carrying the SNP in the 
IRGM gene were more prone to suffer from primary 
non response to IFX (p =  0.009, OR 12.2, CI 1.2–78.8, 
corrected for age) whereas there were no associations 
between the IRGM risk allele and IFX use and response 
in CD patients (corrected for age and fistula).
Regarding ADA, patients carrying the IRGM risk 
allele more often used ADA, compared to patients 
who did not carry this risk allele (p =  0.021, OR 0.58, 
CI 0.36–0.92 corrected for age, IBD subtype and extra 
intestinal manifestations). Sub analysis for CD patients 
only did not show any associations between the IRGM 
SNP and ADA.
XBP1 risk allele carriers responded less to IFX 
(p  =  0.016, OR 3.7, CI 1.2–10.8) and patients carry-
ing a STAT3 SNP more often had side effects on IFX 
(p  =  0.021, OR 0.30, CI 0.11–0.83). No associations 
were found between the risk allele carriers of the NOD2, 
LRRK2/MUC19, CCR6, IL23R and NCF4 genes and 
response to anti-TNFα. As only 13 UC + IBDU patients 
were treated with ADA, no further analysis could be 
performed. An overview of the outcomes of the logistic 
regression can be found in Table 4.
Discussion
Personalized medicine for IBD is called for, as a lack of 
identification of the appropriate patient group may result 
in underestimation of clinical results of some treatments. 
For instance, studies with the granulocyte colony stimu-
lating factor (GM-CSF) sargramostim have been contro-
versial [33–35]. However, granulocytes of CD patients 
carrying the NCF4 risk allele were recently shown to be 
less sensitive to stimulation with GM-CSF, suggesting 
that only a subpopulation of patients may actually ben-
efit from this treatment [24]. Similarly, trials on the use 
of interferon-β-1α (IFN-β-1α) in IBD initially did not 
seem to be effective [36, 37], while on closer inspection, 
Croatian and Russian patients were shown to have high 
remission and response rates using this treatment, while 
Western European populations experienced the opposite 
[36]. These studies emphasise the diversity in IBD, and 
suggest that in study populations, genetic variants could 
be used to stratify groups of patients, potentially leading 
to a tailored treatment model.
The purpose of our study was to investigate putative 
links between IBD-risk alleles and the effect of anti-TNFα 
Table 2 Genetic profile patients
Number of patients that could be analysed for each gene, and the distribution of risk alleles in these genes. All numbers are expressed as n
Gene SNP Total Homozygous: no SNP Heterozygous, one SNP Homozygous, two SNPs
IRGM C 568 430 120 18
ATG16L1 T 559 103 272 184
NOD2 T, C, C 570 428 128 14
rs2066844 T 559 484 71 4
rs2066845 C 567 539 27 1
rs2066847 C 561 513 48 0
XBP1 C, protective 567 510 54 3
LRRK2/MUC19 T 562 532 30 0
CCR6 A 558 135 280 143
IL23R G, protective 564 524 38 2
STAT3 T 562 218 266 78
NCF4 C 570 282 225 63
Table 3 Minor allele frequencies of investigated SNPs 
in general population (controls), as reported for IBD (IBD) 
and in the IBD cohort described here (cohort)
MAF minor allele frequency, SNP single nucleotide polymorphism
Treatment SNP MAF controls 
[31]
MAF IBD 
[31]
MAF cohort
IRGM C 0.13 0.18 0.14
ATG16L1 T 0.48 0.40 [44] 0.57
NOD2 T, C, C – –
rs2066844 T 0.07 0.14 0.07
rs2066845 C 0.01 0.05 0.03
rs2066847 C 0.02 0.11 0.04
XBP1 C, protective 0.04 0.04 0.05
LRRK2/MUC19 T 0.02 0.03 0.03
CCR6 A 0.47 0.48 0.50
IL23R G, protective 0.08 0.02 0.04
STAT3 T 0.42 0.41 0.38
NCF4 C 0.33 0.38 [31, 
45, 46]
0.31
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treatment, something which has received relatively lit-
tle attention to date. For five of the nine investigated 
genes, no association was found with treatment response, 
whereas with three other genes (IRGM, XBP1, STAT3) 
associations were found, but were not strong enough to 
survive multiple testing corrections. The strongest asso-
ciation observed was a tendency for ATG16L1 SNP car-
rying patients to be treated with ADA, with increased 
odds for using ADA when carrying two ATG16L1 risk 
alleles (not shown). Recently, a retrospective study of 
588 IBD patients investigated 41 IBD risk genes, includ-
ing the nine in the current study, and showed that only 
the XBP1 variant was nominally associated with start of 
IFX/ADA [38]. However, unlike the current study, this 
study was performed in a pediatric cohort. Interest-
ingly, a prospective study testing 31 risk-alleles (including 
NOD2, ATG16L1 and IL23R) in 102 patients showed that 
only polymorphisms in ATG16L1 correlated to clinical 
response, with patients carrying the ATG16L1 risk alleles 
having significantly better response to ADA. Although 
ATG16L1 SNP status was associated with use of ADA in 
our study, we did not find primary non-response, side-
effects or loss or response to anti-TNFα to be modulated 
by any of the SNPs studied. However, unlike the other 
three measured outcomes, treatment use in itself is not 
likely a parameter that is influenced by patient genetics, 
as treatment of patients is decided by physicians and SNP 
status in this study was not available to treating physi-
cians. Hence, these results hint at an underlying disease 
phenotype which is not captured by the currently used 
parameters (Montreal score, disease location, disease 
severity). If true, this would suggest that based on genet-
ics, it might be possible to define patient groups with 
subtly different disease, that cannot otherwise be distin-
guished, which opens up an interesting avenue of inves-
tigation. Attempts have already been made to categorize 
CD patients into genetic-based Crohn’s disease sub-
groups according to SNPs in 46 disease susceptibility loci 
[39]. Surprisingly, these genetic-based subgroups could 
not be explained by clinical phenotypic variables such as 
disease location and behaviour, suggesting that patients 
had been categorized into previously un-identified sub-
groups by genetically-determined pathways rather than 
the currently used classifications that are mostly based 
on disease location [39].
A direct comparison between genetic studies is compli-
cated by differences in either cohort size, disease pheno-
type and age of onset. Furthermore, differences in genetic 
associations between disease location and behaviour 
might be found in a different minor allele frequency dis-
tribution between cohorts. While NOD2 and ATG16L1 
variants are some of the most consistently observed IBD-
associated loci, association studies differ per cohort. We 
have investigated only nine of the ~ 200 IBD related risk 
genes, while interactions between SNPs in different genes 
might also account for specific phenotypes [40–42]. Only 
around 13 and 8.2% of disease variance of CD and UC, 
respectively, has been explained by the risk loci identified 
to date, and other genes or epigenetic events may con-
tribute to various extents in these cohorts [15, 43].
Table 4 SNP versus treatment logistic regression
Logistic regression analysis showing the association between the different IBD risk genes and clinical response to anti-TNFα treatments
SNP single nucleotide polymorphism, ns not significant, OR odds ratio, CI confidence interval
Treatment IRGM ATG16L1 NOD2 XBP1 LRRK2/
MUC19
CCR6 IL23 STAT3 NCF4
Requirement
 Infliximab ns ns OR 0.62, CI 
0.41–0.95
ns ns ns ns ns ns
 Adalimumab OR 0.57, CI 
0.36–0.91
OR 2.4, CI 
1.3–4.4
ns ns ns ns ns ns ns
Side-effects
 Infliximab ns ns ns ns ns ns ns OR 0.19, CI 
0.05–0.78
ns
 Adalimumab ns ns ns ns ns ns ns ns ns
Loss of response
 Infliximab ns ns ns ns ns ns ns ns ns
 Adalimumab ns ns ns ns ns ns ns ns ns
Primary non response
 Infliximab OR 2.8, CI 
1.1–7.0
ns ns OR 3.8, CI 
1.2–12.0
ns ns ns ns ns
 Adalimumab ns ns ns ns ns ns ns ns ns
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Conclusions
In conclusion, genetic polymorphisms in the ATG16L1 
gene correlate with ADA treatment, for which a previ-
ously unidentified disease phenotype may be responsible. 
This suggests that genetic make-up of IBD patients may 
in future help physicians decide on personalized treat-
ment strategies. Further investigation will need to eluci-
date the implications of these findings and identify the 
corresponding disease phenotype.
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